TNF and coronary artery disorder: In clinical research, specific disease-modifying drugs (e.g., methotrexate and tumor necrosis factor (TNF) inhibitors) effectively control inflammation and frequently used in RA but not in prevention of CAD, also reduce CAD risk but with many limitations such as side effects, limited targets and absence of studies on effects and safety in depth [12].